MainboardGMP
LIVE
LIVE GMP
MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·
Home › IPOs › Beta Drugs Ltd.
BE
Beta Drugs Ltd.
CLOSED NSE SME Fixed Price IPO Fresh Capital Beta Drugs IPO GMP
GREY MARKET PREMIUM
₹ 0
No premium data
EST. LISTING PRICE
₹85
Issue Price: ₹ 85
Issue Price
₹85
Face Value
₹10
Lot Size
1,600 shares
Open Date
29 Sep 2017
Close Date
04 Oct 2017
Listing Date
12 Oct 2017
Exchange
NSE SME
Beta Drugs IPO About the Company

Beta Drugs Limited is pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. Beta Drugs is primarily engaged in the manufacturing of oncology products. The products include anti-cancer tablets, capsules, injections and lyophilized injections. Company has portfolio of over 50 products which is used for the treatment of various cancer diseases.

Beta Drugs Limited is a part of Adley Group, which was founded in the year 1985. Company's manufacturing unit is located at Solan, Himachal Pradesh.

Company Strengths:
1. Focus on oncology segment. Manufacture over 50 products in this segment.
2. 18 product registrations in various countries. Company is in-process of making additional 12 applications for product registration in various countries.

...read more
Beta Drugs IPO Objects of the Issue
Purpose Amount (₹ Cr)
Purchase of new plant and machinery and upgradtion of the existing plant and machinery ₹7
Civil Construction work at existing manufacturing unit. ₹1
To obtain registration of European Union GMP & Pharmaceutical Inspection Co-operation Scheme ₹1
Working Capital ₹3
General Corporate Purpose ₹4
Beta Drugs IPO Lead Managers
Pantomath Capital Advisors Pvt.Ltd
Issue Details
Total Shares Offered
2,296,000 (100%)
Reserved for Market Maker
Up to ₹1 Cr
Net Offer to Public
Up to ₹18 Cr
Pre-Issue Shareholding
6,335,500 shares
Post-Issue Shareholding
8,649,500 shares
UPI Mandate
04 Oct 2017
IPO Analytics Dashboard
LIVE
Beta Drugs IPO GMP Insights
👤
Retail Demand
Strong
💼
HNI Interest
Strong
📊
Valuation
Moderate
Beta Drugs IPO GMP Strength Score
8 / 10 Strong
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Beta Drugs IPO Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
💼 NII / HNI — 1,083,200 (47%) —
👤 Retail (RII) — 1,083,200 (47%) —
📊 Market Maker — 129,600 (6%) —
Σ Total — 2,296,000 (100%) —

* Amount calculated at upper price band (₹85) ·  ** Total includes all investor categories

Subscription Overview Share allocation by investor category
💼
NII / HNI ? 1,083,200 (47%)
47%
👤
Retail (RII) ? 1,083,200 (47%)
47%
📊
Market Maker ? 129,600 (6%)
6%
Total Shares Offered 2,296,000 (100%)
Beta Drugs IPO Application Sizing Minimum investment by category
👤 Retail Investors ?
Min. Lots 1
Shares / Lot 1,600
Min. Investment ₹136,000
💼 HNI Investors ?
Min. Lots 2
Min. Shares 3,200
Min. Investment ₹272,000
Investor Interpretation
  • Retail allocation is strong at 47% of the total offering.
  • HNI/NII demand is strong at 47%.

This IPO shows strong fundamentals and healthy investor demand. Research the business model and compare with sector peers before applying.

STOCK PRICE HISTORY  ·  NSE
—
Issue Price: ₹ 85  ·  Symbol: —
H —
L —
O —
Beta Drugs IPO Company Info
📍 Village, Nandpur Baddi, Himachal Pradesh, 17410
Visit Website
Beta Drugs IPO Registrar
MUFG Intime India Pvt.Ltd
✉️ -
Check Allotment Status
Beta Drugs IPO FAQs
Beta Drugs IPO has already listed. Its last recorded GMP was ₹0. GMP is only indicative and never a guarantee of listing gains.
The issue price of Beta Drugs IPO is ₹85 per share. One lot has 1,600 shares, so the minimum investment is about ₹136,000. It is a Fresh Capital issue.
Beta Drugs IPO opened on 29 Sep 2017 and closed on 04 Oct 2017. Shares are listed on NSE SME on 12 Oct 2017.
Beta Drugs Limited is pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. Beta Drugs is primarily engaged in the manufacturing of oncology products.
As per the offer document, Beta Drugs plans to use the IPO proceeds for: Purchase of new plant and machinery and upgradtion of the existing plant and machinery (₹7); Civil Construction work at existing manufacturing unit. (₹1); To obtain registration of European Union GMP & Pharmaceutical Inspection Co-operation Scheme (₹1); Working Capital (₹3); General Corporate Purpose (₹4).
The lead manager of Beta Drugs IPO is Pantomath Capital Advisors Pvt.Ltd.
Beta Drugs IPO is proposed to list on NSE SME; it is a Fixed Price IPO and the issue is a Fresh Capital.
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.